No Data
No Data
Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose more than 26%, leading the innovative drug concept, ASCO catalyzes market conditions, institutions are optimistic about policy+health insurance marginal improvement
Zhitong Finance App learned that innovative drug concept stocks showed strong performance. As of press release, Cornerstone Pharmaceutical-B (02616) rose 26.14% to HK$1.11; Cansino Biotech (06185) rose 16.91% to HK$20.95; Gacos-B (01167) rose 14.2% to HK$1.93; Nuocheng Jianhua (09969) rose 12.31% to HK$5.2; Rongchang Biotech (09995) rose 10.2% to HK$30.8. According to the news, the research title of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was on April 25
Nuocheng Jianhua (09969.HK) will hold a board meeting on May 13 to approve the first quarter results
Glonghui, April 29, 丨 Nuochengjianhua (09969.HK) announced that the company will hold a board meeting on May 13, 2024 to consider and approve the unaudited first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and their announcements.
Capital from the south will cross the Hong Kong River again! What is the “success” of the individual stocks listed in AH and AH?
① Among AH listed companies, the target with the highest premium rate reached 6 times; ② the individual stocks with the most significant performance improvement in 2023 among AH listed companies came from the power equipment industry; ③ H shares in AH listed companies account for relatively high targets mainly central state-owned enterprises.
Nuocheng Jianhua (688428): Hematoma first-mover advantage stabilizes the self-immunity pipeline and the harvest period is approaching
Nuochengjianhua (688428.SH) is a commercial-stage biomedical company. Since its establishment in 2015, 2 hematoma products have been approved for sale, and 13 products are in the clinical stage, covering hematomas, immune diseases, and
InnoCare Pharma Limited Expects Multiple Drug Products to Reach Approval
諾誠健華:二零二三年年報
No Data